Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: VOPP1 (ImmuneEditome ID:81552)

1. Gene summary of enriched editing regions for VOPP1

Gene summary

Gene information	Gene symbol	VOPP1
	Gene ID	81552
	GeneSynonyms	ECOP\|GASP\|WBP1L2
	GeneCytomap	7p11.2
	GeneType	protein-coding
	GeneDescription	vesicular, overexpressed in cancer, prosurvival protein 1\|EGFR-coamplified and overexpressed protein\|Glioblastoma-amplified secreted protein\|VOPP1, WBP1/VOPP1 family member\|hypothetical protein DKFZp564K0822\|putative NF-kappa-B-activating protein 055N
	GeneModificationdate	20230329
	UniprotID	Q96AW1;C9JIM1;C9J548;C9JQ18;C9JTY8;C9JF99;C9J827;C9JVH1
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr7:55454226-55459659:-	ENST00000462326.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	L1MA4A,L1PA7	chr7:55454226-55459659:-.alignment
chr7:55461448-55461737:-	ENST00000462326.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	AluSg,L1MA4A	chr7:55461448-55461737:-.alignment
chr7:55508317-55509056:-	ENST00000453112.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	L4_A_Mam,AluJr	chr7:55508317-55509056:-.alignment
chr7:55508317-55509056:-	ENST00000462326.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	L4_A_Mam,AluJr	chr7:55508317-55509056:-.alignment
chr7:55508317-55509056:-	ENST00000471168.1	ENSG00000154978.11	VOPP1	ncRNA_intronic	L4_A_Mam,AluJr	chr7:55508317-55509056:-.alignment
chr7:55508317-55509056:-	ENST00000481197.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	L4_A_Mam,AluJr	chr7:55508317-55509056:-.alignment
chr7:55542632-55543718:-	ENST00000453112.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	AluY,L1MA4,AluSz	chr7:55542632-55543718:-.alignment
chr7:55542632-55543718:-	ENST00000462326.4	ENSG00000154978.11	VOPP1	ncRNA_intronic	AluY,L1MA4,AluSz	chr7:55542632-55543718:-.alignment
chr7:55542632-55543718:-	ENST00000471168.1	ENSG00000154978.11	VOPP1	ncRNA_intronic	AluY,L1MA4,AluSz	chr7:55542632-55543718:-.alignment

Top

2. Tumor-specific enriched editing regions for VOPP1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr7:55454226-55459659:-	COAD	EER	4.9370e-04
ENSG00000154978.11,VOPP1	COAD	EAG	4.8981e-04
chr7:55454226-55459659:-	KIRC	EER	3.6958e-03
ENSG00000154978.11,VOPP1	KIRC	EAG	3.8793e-03
chr7:55454226-55459659:-	LUAD	EER	4.2244e-02
ENSG00000154978.11,VOPP1	LUAD	EAG	4.2513e-02
chr7:55454226-55459659:-	LUSC	EER	2.9723e-04
ENSG00000154978.11,VOPP1	LUSC	EAG	2.9748e-04
chr7:55454226-55459659:-	UCEC	EER	2.7172e-06
ENSG00000154978.11,VOPP1	UCEC	EAG	2.7077e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr7:55454226-55459659:-	KIRP	Path	EER	3.5737e-02	3.4388e-03	0.1874
ENSG00000154978.11,VOPP1	KIRP	Path	EAG	3.5564e-02	3.4187e-03	0.1875
chr7:55454226-55459659:-	LUAD	Path	EER	3.0194e-04	1.4555e-04	0.1740
ENSG00000154978.11,VOPP1	LUAD	Path	EAG	2.9226e-04	1.4310e-04	0.1742
chr7:55454226-55459659:-	READ	Path	EER	2.7548e-02	9.4312e-03	-0.2371
ENSG00000154978.11,VOPP1	READ	Path	EAG	2.7557e-02	9.4322e-03	-0.2371

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr7:55454226-55459659:-	HNSC	EER	8.2100e-03	5.9920e-03	2.3145e+01
ENSG00000154978.11,VOPP1	HNSC	EAG	8.2100e-03	5.9547e-03	2.3210e+01
ENSG00000154978.11,VOPP1	LIHC	EAG	3.9913e-02	3.6735e-02	4.2726e-02

Top

3. Enriched editing regions and immune related genes for VOPP1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr7:55454226-55459659:-

LUAD

EER

ENSG00000139190,VAMP1

-0.4258

7.6415e-18

1.1046e-21

-0.4221

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

Macrophages_M2

GSVA_HALLMARK_ADIPOGENESIS

chr7:55454226-55459659:-

COAD

EER

ENSG00000144504,ANKMY1

-0.3062

7.1163e-05

4.3834e-13

0.4206

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

Dendritic_cells_activated

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr7:55454226-55459659:-

COAD

EER

ENSG00000207129,RNA5SP187

-0.2550

1.5281e-03

1.5868e-12

0.4113

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:55454226-55459659:-

COAD

EER

ENSG00000250067,YJEFN3

-0.2412

3.7754e-03

2.7088e-12

0.4073

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

YJEFN3

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:55454226-55459659:-

COAD

EER

ENSG00000279392,AL158801.1

0.2370

4.1907e-03

1.9970e-12

0.4096

Macrophages_M0

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr7:55454226-55459659:-

COAD

EER

ENSG00000268836,LA16c-OS12.2

-0.2279

7.5986e-03

1.6634e-20

0.5231

CSTF2T;DDX54;ELAVL1;FMR1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;NOP56;NOP58;RBM10;TAF15;TIA1;U2AF2

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:55454226-55459659:-

COAD

EER

ENSG00000237973,RP5-857K21.6

-0.2151

1.2812e-02

4.1375e-12

0.4041

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:55454226-55459659:-

COAD

EER

ENSG00000267523,CTD-2537I9.12

-0.2078

1.6701e-02

4.7511e-30

0.6180

DKC1;ELAVL1;FBL;NOP56;TAF15;UPF1

Dendritic_cells_activated

GSVA_HALLMARK_ADIPOGENESIS

chr7:55454226-55459659:-

COAD

EER

ENSG00000093217,XYLB

0.1781

4.7957e-02

4.3186e-22

0.5411

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS2;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

Dendritic_cells_activated

GSVA_HALLMARK_P53_PATHWAY

chr7:55454226-55459659:-

LUSC

EER

ENSG00000268087,CTC-429P9.2

-0.4459

1.1965e-19

2.3253e-21

-0.4157

EIF4A3;ELAVL1;NOP56;TAF15;U2AF2;UPF1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_GLYCOLYSIS

More results

Top

4. Enriched editing regions and immune related splicing for VOPP1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr7:55454226-55459659:-

COAD

EER

ENSG00000105397.9

chr19

10364850:10365048:10365516:10365808

-0.2601

4.4810e-03

1.0416e-14

0.4522

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

TYK2

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000154978.11,VOPP1

COAD

EAG

ENSG00000111653.15

chr12

6652661:6652767:6652935:6653050

-0.3826

4.6521e-07

3.1081e-11

-0.4003

AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;UPF1;YTHDF1

ING4

B_cells_memory

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:55454226-55459659:-

COAD

EER

ENSG00000160190.9

chr21

42579470:42579800:42580344:42581440

-0.2805

1.3124e-03

1.3090e-11

0.4015

CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;HNRNPA1;HNRNPC;IGF2BP2;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;U2AF2;UPF1

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000154978.11,VOPP1

COAD

EAG

ENSG00000104885.13

chr19

2225387:2225452:2226182:2227127

-0.2678

3.3583e-03

1.2595e-11

0.4061

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS3;LARP7;LIN28;LIN28A;LIN28B;MBNL2;METTL14;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM5;SF3A3;SF3B4;SLBP;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF2;UPF1;YTHDC1;YTHDF1

Eosinophils

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:55454226-55459659:-

COAD

EER

ENSG00000129235.6

chr17

6640757:6641227:6641752:6641834

-0.3562

5.9531e-06

1.8025e-14

0.4447

CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;HNRNPA1;HNRNPU;IGF2BP2;KHDRBS1;KHDRBS2;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

TXNDC17

Eosinophils

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000154978.11,VOPP1

COAD

EAG

ENSG00000124574.10

chr6

43446276:43446446:43447247:43447408

-0.2386

1.5932e-02

4.7736e-13

0.4287

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF2;UPF1;YTHDC1;YTHDF1

Eosinophils

GSVA_HALLMARK_ADIPOGENESIS

ENSG00000154978.11,VOPP1

COAD

EAG

ENSG00000182004.8

chr1

203861614:203861713:203862195:203862222

-0.2771

3.3966e-03

2.6124e-22

0.5435

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF2;UPF1;YTHDC1

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:55454226-55459659:-

COAD

EER

ENSG00000133030.15

chr17

17175292:17175412:17176425:17176512

-0.2859

1.4040e-03

2.5098e-16

0.4704

BCCIP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;KHDRBS2;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:55454226-55459659:-

COAD

EER

ENSG00000120832.5

chr12

106985114:106985225:106986968:106987090

-0.3161

6.1108e-06

4.0428e-10

-0.4108

BCCIP;CSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHDRBS1;KHDRBS2;NOP56;NOP58;PRPF8;RBFOX2;RBM10;TAF15;TIA1;U2AF2;UPF1

Macrophages_M1

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000154978.11,VOPP1

COAD

EAG

ENSG00000176731.7

chr8

85214555:85214631:85214920:85215037:85217385:85217502

-0.2254

4.1613e-02

6.7432e-17

-0.4775

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS3;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TIA1;TNRC6A;TROVE2;U2AF2;UPF1

NK_cells_resting

GSVA_HALLMARK_BILE_ACID_METABOLISM

More results

Top

5. Enriched editing regions and immune infiltration for VOPP1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr7:55454226-55459659:-	BLCA	EER	T_cells_CD4_memory_resting	5.1501e-03	-0.1486
ENSG00000154978.11,VOPP1	BLCA	EAG	T_cells_CD4_memory_resting	5.2811e-03	-0.1482
chr7:55454226-55459659:-	BRCA	EER	T_cells_CD4_memory_resting	2.5964e-07	-0.1587
ENSG00000154978.11,VOPP1	BRCA	EAG	B_cells_naive	2.6882e-07	-0.1585
chr7:55454226-55459659:-	CESC	EER	Dendritic_cells_activated	6.0369e-05	0.2374
ENSG00000154978.11,VOPP1	CESC	EAG	Dendritic_cells_activated	6.0419e-05	0.2373
chr7:55454226-55459659:-	CHOL	EER	T_cells_CD4_naive	5.5796e-05	0.6423
ENSG00000154978.11,VOPP1	CHOL	EAG	T_cells_CD4_naive	5.5796e-05	0.6423
chr7:55454226-55459659:-	COAD	EER	Dendritic_cells_activated	9.6448e-05	0.2342
ENSG00000154978.11,VOPP1	COAD	EAG	Dendritic_cells_activated	9.7388e-05	0.2341
chr7:55454226-55459659:-	DLBC	EER	Monocytes	8.3153e-04	0.4758
ENSG00000154978.11,VOPP1	DLBC	EAG	Monocytes	8.1114e-04	0.4767
chr7:55454226-55459659:-	ESCA	EER	T_cells_CD4_memory_resting	3.5577e-06	-0.3593
chr7:55461448-55461737:-	ESCA	EER	T_cells_CD4_memory_resting	2.0969e-02	-0.3135
ENSG00000154978.11,VOPP1	ESCA	EAG	T_cells_CD4_memory_resting	3.4425e-06	-0.3598
chr7:55454226-55459659:-	GBM	EER	T_cells_follicular_helper	2.1237e-03	-0.2412
ENSG00000154978.11,VOPP1	GBM	EAG	T_cells_follicular_helper	2.4847e-03	-0.2376
chr7:55454226-55459659:-	HNSC	EER	T_cells_regulatory_(Tregs)	4.6992e-07	-0.2440
ENSG00000154978.11,VOPP1	HNSC	EAG	T_cells_regulatory_(Tregs)	4.7156e-07	-0.2440
chr7:55454226-55459659:-	KICH	EER	Macrophages_M0	1.4584e-02	0.3089
ENSG00000154978.11,VOPP1	KICH	EAG	Macrophages_M0	1.4653e-02	0.3087
chr7:55454226-55459659:-	KIRC	EER	Dendritic_cells_activated	1.4511e-05	0.2204
ENSG00000154978.11,VOPP1	KIRC	EAG	Dendritic_cells_activated	1.2975e-05	0.2216
chr7:55454226-55459659:-	KIRP	EER	NK_cells_resting	2.2174e-03	0.1858
ENSG00000154978.11,VOPP1	KIRP	EAG	NK_cells_resting	2.2162e-03	0.1858
chr7:55454226-55459659:-	LAML	EER	Mast_cells_resting	7.2539e-03	0.2860
ENSG00000154978.11,VOPP1	LAML	EAG	Mast_cells_resting	4.4347e-03	0.3023
chr7:55454226-55459659:-	LGG	EER	T_cells_CD4_naive	1.4091e-05	0.1895
ENSG00000154978.11,VOPP1	LGG	EAG	T_cells_CD4_naive	1.3688e-05	0.1898
chr7:55454226-55459659:-	LIHC	EER	T_cells_CD4_naive	4.1580e-02	0.1241
ENSG00000154978.11,VOPP1	LIHC	EAG	T_cells_CD4_naive	4.1305e-02	0.1240
chr7:55454226-55459659:-	LUAD	EER	T_cells_CD4_memory_resting	2.1446e-03	-0.1414
ENSG00000154978.11,VOPP1	LUAD	EAG	T_cells_CD4_memory_resting	2.1526e-03	-0.1413
chr7:55454226-55459659:-	LUSC	EER	T_cells_gamma_delta	1.4370e-02	0.1120
ENSG00000154978.11,VOPP1	LUSC	EAG	T_cells_gamma_delta	1.4401e-02	0.1120
chr7:55454226-55459659:-	MESO	EER	B_cells_naive	2.9814e-03	-0.3341
ENSG00000154978.11,VOPP1	MESO	EAG	B_cells_naive	2.9825e-03	-0.3341
chr7:55454226-55459659:-	OV	EER	T_cells_CD8	1.6561e-04	0.2248
ENSG00000154978.11,VOPP1	OV	EAG	T_cells_CD8	1.3936e-04	0.2273
chr7:55454226-55459659:-	PAAD	EER	Neutrophils	5.4299e-06	0.3389
ENSG00000154978.11,VOPP1	PAAD	EAG	Neutrophils	5.4327e-06	0.3389
chr7:55454226-55459659:-	PRAD	EER	T_cells_regulatory_(Tregs)	3.2241e-04	-0.1770
ENSG00000154978.11,VOPP1	PRAD	EAG	T_cells_regulatory_(Tregs)	3.1974e-04	-0.1771
chr7:55454226-55459659:-	READ	EER	Macrophages_M0	4.2105e-03	-0.2942
ENSG00000154978.11,VOPP1	READ	EAG	Macrophages_M0	4.2487e-03	-0.2939
chr7:55454226-55459659:-	SARC	EER	Eosinophils	3.4673e-03	0.1888
ENSG00000154978.11,VOPP1	SARC	EAG	Eosinophils	3.4680e-03	0.1888
chr7:55454226-55459659:-	SKCM	EER	T_cells_regulatory_(Tregs)	1.3250e-04	-0.2644
ENSG00000154978.11,VOPP1	SKCM	EAG	T_cells_regulatory_(Tregs)	1.3252e-04	-0.2644
chr7:55454226-55459659:-	STAD	EER	T_cells_CD4_memory_resting	3.8253e-06	-0.2373
ENSG00000154978.11,VOPP1	STAD	EAG	T_cells_CD4_memory_resting	2.1426e-06	-0.2432
chr7:55454226-55459659:-	TGCT	EER	Macrophages_M2	9.6038e-04	0.3039
ENSG00000154978.11,VOPP1	TGCT	EAG	Macrophages_M2	9.6038e-04	0.3039
chr7:55454226-55459659:-	THCA	EER	Dendritic_cells_activated	4.3988e-03	0.1360
ENSG00000154978.11,VOPP1	THCA	EAG	Dendritic_cells_activated	4.2091e-03	0.1367
chr7:55454226-55459659:-	THYM	EER	Mast_cells_resting	1.3158e-05	0.4372
ENSG00000154978.11,VOPP1	THYM	EAG	Mast_cells_resting	1.3158e-05	0.4372
chr7:55454226-55459659:-	UCEC	EER	T_cells_CD4_memory_resting	9.3445e-03	-0.2043
ENSG00000154978.11,VOPP1	UCEC	EAG	T_cells_CD4_memory_resting	9.5113e-03	-0.2038
chr7:55454226-55459659:-	UCS	EER	Dendritic_cells_activated	1.4991e-02	0.3389
ENSG00000154978.11,VOPP1	UCS	EAG	Dendritic_cells_activated	1.4991e-02	0.3389

Top

6. Enriched editing regions and immune gene sets for VOPP1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr7:55454226-55459659:-	STAD	EER	3.3928e-02		2.3970e-03	0.1572
ENSG00000154978.11,VOPP1	STAD	EAG	3.6444e-02		2.6119e-03	0.1558

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr7:55454226-55459659:-	BRCA	EER	4.5668e-17	0.2561	1.5343e-07	0.1617	4.9778e-19	0.2712	4.0016e-04	0.1095
ENSG00000154978.11,VOPP1	BRCA	EAG	5.5604e-17	0.2554	1.5348e-07	0.1617	6.2206e-19	0.2705	4.9764e-04	0.1077
ENSG00000154978.11,VOPP1	ESCA	EAG	3.7992e-14	0.5550	3.0286e-03	0.2344	4.2447e-12	0.5154	4.2696e-03	0.2262
chr7:55454226-55459659:-	ESCA	EER	3.3221e-14	0.5561	2.9033e-03	0.2354	4.1076e-12	0.5157	4.1008e-03	0.2272
chr7:55454226-55459659:-	LUAD	EER	6.1190e-05	0.1840	1.5563e-02	0.1116	5.4775e-04	0.1590	3.9513e-09	0.2675
ENSG00000154978.11,VOPP1	LUAD	EAG	6.1021e-05	0.1840	1.5621e-02	0.1116	5.4529e-04	0.1591	3.6632e-09	0.2681
chr7:55454226-55459659:-	LUSC	EER	8.0803e-10	0.2765	1.0396e-02	0.1172	1.8109e-06	0.2165	1.1881e-03	0.1480
ENSG00000154978.11,VOPP1	LUSC	EAG	8.1185e-10	0.2765	1.0333e-02	0.1173	1.8201e-06	0.2165	1.1921e-03	0.1480
ENSG00000154978.11,VOPP1	STAD	EAG	1.1791e-14	0.3864	1.3563e-03	0.1657	8.4950e-11	0.3287	4.4114e-10	0.3166
chr7:55454226-55459659:-	STAD	EER	8.1744e-15	0.3885	1.0111e-03	0.1700	7.1819e-11	0.3299	2.6873e-10	0.3203

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000154978.11,VOPP1	ACC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.8036e-02	0.3521
chr7:55454226-55459659:-	ACC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	3.8036e-02	0.3521
ENSG00000154978.11,VOPP1	BLCA	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.7748e-04	0.1983
chr7:55454226-55459659:-	BLCA	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	1.6595e-04	0.1991
ENSG00000154978.11,VOPP1	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	5.6913e-34	0.3639
chr7:55454226-55459659:-	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EER	2.7787e-34	0.3655
chr7:55454226-55459659:-	CESC	GSVA_HALLMARK_HYPOXIA	EER	2.5073e-07	0.3023
ENSG00000154978.11,VOPP1	CESC	GSVA_HALLMARK_HYPOXIA	EAG	2.5080e-07	0.3023
chr7:55454226-55459659:-	COAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.5388e-06	0.2866
ENSG00000154978.11,VOPP1	COAD	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.6142e-06	0.2861
ENSG00000154978.11,VOPP1	DLBC	GSVA_HALLMARK_HEME_METABOLISM	EAG	3.0756e-02	-0.3189
chr7:55454226-55459659:-	DLBC	GSVA_HALLMARK_HEME_METABOLISM	EER	2.9858e-02	-0.3206
chr7:55454226-55459659:-	ESCA	GSVA_HALLMARK_MYC_TARGETS_V1	EER	7.4849e-09	0.4397
chr7:55461448-55461737:-	ESCA	GSVA_HALLMARK_PEROXISOME	EER	9.4962e-03	0.3499
ENSG00000154978.11,VOPP1	ESCA	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	9.7435e-09	0.4366
chr7:55454226-55459659:-	GBM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.5774e-09	0.4544
ENSG00000154978.11,VOPP1	GBM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.2322e-09	0.4571
chr7:55454226-55459659:-	HNSC	GSVA_HALLMARK_P53_PATHWAY	EER	1.6830e-10	0.3065
ENSG00000154978.11,VOPP1	HNSC	GSVA_HALLMARK_P53_PATHWAY	EAG	1.6914e-10	0.3065
chr7:55454226-55459659:-	KICH	GSVA_HALLMARK_DNA_REPAIR	EER	6.1775e-03	-0.3441
ENSG00000154978.11,VOPP1	KICH	GSVA_HALLMARK_DNA_REPAIR	EAG	6.2038e-03	-0.3439
chr7:55454226-55459659:-	KIRC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	5.6266e-25	0.4959
ENSG00000154978.11,VOPP1	KIRC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	9.1608e-25	0.4939
chr7:55454226-55459659:-	KIRP	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	7.1088e-07	0.2969
ENSG00000154978.11,VOPP1	KIRP	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.0579e-07	0.2969
ENSG00000154978.11,VOPP1	LAML	GSVA_HALLMARK_APICAL_SURFACE	EAG	1.2311e-03	-0.3409
chr7:55454226-55459659:-	LAML	GSVA_HALLMARK_APICAL_SURFACE	EER	1.1505e-03	-0.3429
ENSG00000154978.11,VOPP1	LGG	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	1.0558e-05	-0.1922
chr7:55454226-55459659:-	LGG	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.0960e-05	-0.1919
chr7:55454226-55459659:-	LIHC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	5.6557e-07	0.2988
ENSG00000154978.11,VOPP1	LIHC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	5.4531e-07	0.2987
ENSG00000154978.11,VOPP1	LUAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	7.9118e-21	0.4138
chr7:55454226-55459659:-	LUAD	GSVA_HALLMARK_ADIPOGENESIS	EER	8.1698e-21	0.4137
ENSG00000154978.11,VOPP1	LUSC	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.8559e-17	0.3759
chr7:55454226-55459659:-	LUSC	GSVA_HALLMARK_GLYCOLYSIS	EER	1.8771e-17	0.3759
ENSG00000154978.11,VOPP1	MESO	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	3.4100e-03	0.3297
chr7:55454226-55459659:-	MESO	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	3.4055e-03	0.3297
chr7:55461448-55461737:-	OV	GSVA_HALLMARK_DNA_REPAIR	EER	4.8578e-02	0.3694
ENSG00000154978.11,VOPP1	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.5344e-15	0.4554
chr7:55454226-55459659:-	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.5791e-15	0.4553
chr7:55454226-55459659:-	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.8391e-03	0.2194
ENSG00000154978.11,VOPP1	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.8598e-03	0.2192
ENSG00000154978.11,VOPP1	PCPG	GSVA_HALLMARK_HEME_METABOLISM	EAG	3.6330e-05	0.3223
chr7:55454226-55459659:-	PCPG	GSVA_HALLMARK_HEME_METABOLISM	EER	3.6271e-05	0.3223
chr7:55454226-55459659:-	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EER	1.3084e-09	0.2942
ENSG00000154978.11,VOPP1	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	1.3519e-09	0.2940
ENSG00000154978.11,VOPP1	READ	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.6644e-07	0.5110
chr7:55454226-55459659:-	READ	GSVA_HALLMARK_GLYCOLYSIS	EER	1.6689e-07	0.5109
ENSG00000154978.11,VOPP1	SARC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.4984e-03	0.2047
chr7:55454226-55459659:-	SARC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.5052e-03	0.2046
ENSG00000154978.11,VOPP1	SKCM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	7.3741e-08	-0.3659
chr7:55454226-55459659:-	SKCM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	7.3754e-08	-0.3659
chr7:55454226-55459659:-	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.0947e-21	0.4643
ENSG00000154978.11,VOPP1	STAD	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	8.8916e-21	0.4595
chr7:55454226-55459659:-	TGCT	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.5381e-05	0.3756
ENSG00000154978.11,VOPP1	TGCT	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.5381e-05	0.3756
chr7:55454226-55459659:-	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	7.5682e-09	0.2719
ENSG00000154978.11,VOPP1	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	5.3148e-09	0.2746
chr7:55454226-55459659:-	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.9525e-03	0.3066
ENSG00000154978.11,VOPP1	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.9525e-03	0.3066
chr7:55454226-55459659:-	UCEC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.6215e-04	0.2839
ENSG00000154978.11,VOPP1	UCEC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.7010e-04	0.2834
ENSG00000154978.11,VOPP1	UCS	GSVA_HALLMARK_SPERMATOGENESIS	EAG	8.9034e-04	0.4512
chr7:55454226-55459659:-	UCS	GSVA_HALLMARK_SPERMATOGENESIS	EER	8.9034e-04	0.4512

Top

7. Enriched editing regions and drugs for VOPP1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000154978.11,VOPP1	BLCA	A.443654	EAG	2.6412e-03	-0.1596
chr7:55454226-55459659:-	BLCA	A.443654	EER	2.4084e-03	-0.1610
ENSG00000154978.11,VOPP1	BRCA	GDC0941	EAG	2.5570e-22	0.2947
chr7:55461448-55461737:-	BRCA	Dasatinib	EER	9.1472e-03	-0.5203
chr7:55454226-55459659:-	BRCA	GDC0941	EER	2.2750e-22	0.2950
ENSG00000154978.11,VOPP1	CESC	FTI.277	EAG	3.6537e-07	-0.2983
chr7:55454226-55459659:-	CESC	FTI.277	EER	3.6505e-07	-0.2984
ENSG00000154978.11,VOPP1	CHOL	GW843682X	EAG	1.4793e-03	0.5309
chr7:55454226-55459659:-	CHOL	GW843682X	EER	1.4793e-03	0.5309
chr7:55454226-55459659:-	COAD	BI.D1870	EER	6.9657e-03	-0.1633
ENSG00000154978.11,VOPP1	COAD	BI.D1870	EAG	6.9467e-03	-0.1633
chr7:55454226-55459659:-	DLBC	Erlotinib	EER	6.0929e-03	-0.3985
ENSG00000154978.11,VOPP1	DLBC	Erlotinib	EAG	6.3461e-03	-0.3967
chr7:55461448-55461737:-	ESCA	JW.7.52.1	EER	7.4917e-03	-0.3600
ENSG00000154978.11,VOPP1	ESCA	Docetaxel	EAG	3.9703e-10	-0.4716
chr7:55454226-55459659:-	ESCA	Docetaxel	EER	3.4072e-10	-0.4732
chr7:55454226-55459659:-	GBM	MG.132	EER	1.4300e-07	-0.4015
ENSG00000154978.11,VOPP1	GBM	MG.132	EAG	1.6291e-07	-0.3998
ENSG00000154978.11,VOPP1	HNSC	AUY922	EAG	1.2774e-06	-0.2348
chr7:55454226-55459659:-	HNSC	AUY922	EER	1.2848e-06	-0.2348
chr7:55454226-55459659:-	KICH	Bortezomib	EER	4.9627e-03	0.3524
ENSG00000154978.11,VOPP1	KICH	Bortezomib	EAG	4.9554e-03	0.3525
ENSG00000154978.11,VOPP1	KIRC	ATRA	EAG	1.1343e-19	0.4427
chr7:55454226-55459659:-	KIRC	ATRA	EER	8.2144e-20	0.4443
chr7:55454226-55459659:-	KIRP	GW.441756	EER	3.4946e-07	-0.3046
ENSG00000154978.11,VOPP1	KIRP	GW.441756	EAG	3.4668e-07	-0.3047
ENSG00000154978.11,VOPP1	LAML	AZD6482	EAG	7.2303e-05	0.4124
chr7:55454226-55459659:-	LAML	AZD6482	EER	2.8687e-05	0.4325
ENSG00000154978.11,VOPP1	LGG	Cyclopamine	EAG	7.2438e-06	0.1957
chr7:55454226-55459659:-	LGG	Cyclopamine	EER	7.5861e-06	0.1953
ENSG00000154978.11,VOPP1	LIHC	Etoposide	EAG	6.8828e-04	0.2049
chr7:55454226-55459659:-	LIHC	Etoposide	EER	6.6464e-04	0.2059
chr7:55454226-55459659:-	LUAD	Lenalidomide	EER	3.5785e-18	0.3866
ENSG00000154978.11,VOPP1	LUAD	Lenalidomide	EAG	3.4741e-18	0.3868
ENSG00000154978.11,VOPP1	LUSC	CCT007093	EAG	2.3902e-14	0.3397
chr7:55454226-55459659:-	LUSC	CCT007093	EER	2.4104e-14	0.3396
chr7:55454226-55459659:-	MESO	Bosutinib	EER	2.9424e-04	0.4016
ENSG00000154978.11,VOPP1	MESO	Bosutinib	EAG	2.9496e-04	0.4016
chr7:55461448-55461737:-	OV	GW843682X	EER	7.0801e-03	-0.4892
ENSG00000154978.11,VOPP1	OV	BMS.536924	EAG	1.6999e-11	-0.3906
chr7:55454226-55459659:-	OV	BMS.536924	EER	1.5729e-11	-0.3912
ENSG00000154978.11,VOPP1	PAAD	FH535	EAG	3.5263e-09	-0.4335
chr7:55454226-55459659:-	PAAD	FH535	EER	3.5631e-09	-0.4334
ENSG00000154978.11,VOPP1	PCPG	AUY922	EAG	1.2744e-02	-0.1978
chr7:55454226-55459659:-	PCPG	AUY922	EER	1.2684e-02	-0.1979
chr7:55454226-55459659:-	PRAD	Bicalutamide	EER	4.4119e-09	-0.2850
ENSG00000154978.11,VOPP1	PRAD	Bicalutamide	EAG	4.5189e-09	-0.2848
ENSG00000154978.11,VOPP1	READ	CCT007093	EAG	9.1887e-04	0.3381
chr7:55454226-55459659:-	READ	CCT007093	EER	9.1500e-04	0.3382
ENSG00000154978.11,VOPP1	SARC	Metformin	EAG	1.9929e-04	0.2389
chr7:55454226-55459659:-	SARC	Metformin	EER	1.9965e-04	0.2389
chr7:55454226-55459659:-	SKCM	AZD.2281	EER	6.2150e-10	0.4177
ENSG00000154978.11,VOPP1	SKCM	AZD.2281	EAG	6.2211e-10	0.4177
chr7:55454226-55459659:-	STAD	CCT007093	EER	7.2443e-16	0.4023
ENSG00000154978.11,VOPP1	STAD	CCT007093	EAG	6.9354e-16	0.4026
ENSG00000154978.11,VOPP1	TGCT	Erlotinib	EAG	1.9699e-04	-0.3405
chr7:55454226-55459659:-	TGCT	Erlotinib	EER	1.9699e-04	-0.3405
ENSG00000154978.11,VOPP1	THCA	Bicalutamide	EAG	1.9834e-11	-0.3136
chr7:55454226-55459659:-	THCA	Bicalutamide	EER	1.9140e-11	-0.3138
ENSG00000154978.11,VOPP1	THYM	BAY.61.3606	EAG	8.7596e-06	0.4451
chr7:55454226-55459659:-	THYM	BAY.61.3606	EER	8.7596e-06	0.4451
ENSG00000154978.11,VOPP1	UCEC	DMOG	EAG	3.7941e-10	0.4682
chr7:55454226-55459659:-	UCEC	DMOG	EER	3.7033e-10	0.4684
chr7:55454226-55459659:-	UCS	Bosutinib	EER	1.8256e-03	0.4260
ENSG00000154978.11,VOPP1	UCS	Bosutinib	EAG	1.8256e-03	0.4260

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType